CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 6 enrolled
Drug / intervention
3BNC117-LS +1 moredrug
Likely dose
3BNC117-LS 30mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04250636
NCT04250636Phase 1Completed
CompareCT.gov

An Open Label, Single Arm Study of the Safety, Pharmacokinetics and Antiretroviral Activity of the Combination of 3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals.

Rockefeller University·interventional·Posted Jan 31, 2020·Updated Jun 26, 2023

In Brief

A Phase 1 clinical trial evaluating 3BNC117-LS and 10-1074-LS for Human Immunodeficiency Virus. Completed, enrolled 6 participants across 3 sites.

Detailed Summary

The proposed study is a phase 1, open label, single arm study to evaluate the safety, pharmacokinetics and antiviral activity of single intravenous infusions of 3BNC117-LS and 10-1074-LS, each monoclonal antibody (mAb) dosed at 30 mg/kg in viremic human immunodeficiency virus (HIV)-infected individuals.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuman Immunodeficiency Virus
CountriesUnited States
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID), Weill Medical College of Cornell University, University of Pennsylvania

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedJan 31, 2020
Enrollment StartOct 13, 2020
Primary CompletionJan 21, 2022
Study CompletionFeb 11, 2022
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 6.4 years ago

Interventions

3BNC117-LSdrug

Intravenous infusion of 3BNC117-LS at 30mg/kg

10-1074-LSdrug

Intravenous infusion of 10-1074-LS at 30mg/kg